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Abstract
Accumulating evidence supports the role of an aberrant transcriptome as a driver of meta-
static potential. Deadenylation is a general regulatory node for post-transcriptional control
by microRNAs and other determinants of RNA stability. Previously, we demonstrated that
the CCR4-NOT scaffold component Cnot2 is an inherited metastasis susceptibility gene. In
this study, using orthotopic metastasis assays and genetically engineered mouse models,
we show that one of the enzymatic subunits of the CCR4-NOT complex, Cnot7, is also a
metastasis modifying gene. We demonstrate that higher expression of Cnot7 drives tumor
cell autonomous metastatic potential, which requires its deadenylase activity. Furthermore,
metastasis promotion by CNOT7 is dependent on interaction with CNOT1 and TOB1.
CNOT7 ribonucleoprotein-immunoprecipitation (RIP) and integrated transcriptome wide
analyses reveal that CNOT7-regulated transcripts are enriched for a tripartite 3’UTR motif
bound by RNA-binding proteins known to complex with CNOT7, TOB1, and CNOT1. Collec-
tively, our data support a model of CNOT7, TOB1, CNOT1, and RNA-binding proteins col-
lectively exerting post-transcriptional control on a metastasis suppressive transcriptional
program to drive tumor cell metastasis.
Author Summary
The majority of human cancer related death is due to the effects of metastasis, the process
of cancer dissemination to and growth in distant organs. Primarily due to its complexity,
the metastatic process remains incompletely understood. This complexity stems from the
tumor cell’s dependence on multiple cellular and molecular systems for the successful col-
onization of distant sites. In this study, we demonstrate that one of the factors that
PLOSGenetics | DOI:10.1371/journal.pgen.1005820 January 25, 2016 1 / 23
a11111
OPEN ACCESS
Citation: Faraji F, Hu Y, Yang HH, Lee MP, Winkler
GS, Hafner M, et al. (2016) Post-transcriptional
Control of Tumor Cell Autonomous Metastatic
Potential by CCR4-NOT Deadenylase CNOT7. PLoS
Genet 12(1): e1005820. doi:10.1371/journal.
pgen.1005820
Editor: Laura Corbo, Cancer Research Center of
Lyon, FRANCE
Received: October 13, 2015
Accepted: December 31, 2015
Published: January 25, 2016
Copyright: This is an open access article, free of all
copyright, and may be freely reproduced, distributed,
transmitted, modified, built upon, or otherwise used
by anyone for any lawful purpose. The work is made
available under the Creative Commons CC0 public
domain dedication.
Data Availability Statement: All microarray and
RIPseq files are available from the GEOdatabase
(accession numbers GSE73296 and GSE73366).
Funding: This research was supported by the
Intramural Research Program of the NIH, National
Cancer Institute, Center for Cancer Research. The
funders had no role in study design, data collection
and analysis, decision to publish, or preparation of
the manuscript
Competing Interests: The authors have declared
that no competing interests exist.
contributes to metastatic progression is the control of tumor cell RNA stability. Previously,
we demonstrated that a structural component of the CCR4-NOT transcription regulatory
complex was an inherited metastasis susceptibility gene. Here we demonstrate that one of
the enzymatic components of the CCR-NOT complex, Cnot7, is also a metastasis-associ-
ated gene, and that enzymatic activity of Cnot7 is required for its promotion of metastatic
disease. These results suggest that large-scale control of RNA abundance may be modulat-
ing specific metastasis-related transcriptional programs, and that inhibition of specific
RNA deadenylases may be a viable avenue in the development of anti-metastatic
therapeutics.
Introduction
Metastasis is a complex process in which tumor cells disseminate from the primary tumor site
to form life-threatening lesions at distant sites. To successfully complete the metastatic process
tumor cells must activate a series of molecular functions. These include motility and invasion
to escape the primary site and penetrate the parenchyma at the secondary organ, anti-apoptotic
programs to survive anoikis during transit through the lymphatic or hematic vasculature, and
proliferative programs to establish clinically relevant macroscopic lesions [1]. Each of these
programs requires the action of multiple genes in a coordinated fashion. As a result, control of
transcriptional programs in the metastatic cascade has been the focus of many studies over the
past decade. For example, activation of embryonic programs through up-regulation of tran-
scription factors is thought to be important in the migratory and invasive steps of the meta-
static cascade [2, 3]. Post-transcriptional control of metastasis-associated genes by microRNAs
has also been the subject of a variety of studies [e.g. [4, 5]]. Activation or suppression of these
pleiotropic factors, through mutation, amplification, or deletion, therefore plays critical roles
in tumor evolution and progression.
In addition to activation or suppression of whole transcriptional programs, factors that sig-
nificantly alter transcriptional units might also alter the ability of a tumor cell to complete one
or more of the steps of the metastatic cascade. Studies in recent years have demonstrated an
important role for inherited polymorphism in gene expression programs [6, 7] suggesting that
inherited factors can significantly influence tumor phenotypes. Our laboratory previously dem-
onstrated that inherited polymorphisms significantly influence metastatic outcome [8] and
that inheritance plays a role in the establishment of transcriptional profiles that discriminate
patient outcome [9]. More recently we have integrated gene expression analysis and suscepti-
bility genetics studies to identify co-expressed transcriptional networks associated with meta-
static disease. One such network was centered on Cnot2, a scaffolding component of the
CCR4-NOT RNA deadenylase complex [10]. In vivo validation studies demonstrated that
varying CNOT2 levels significantly influenced tumor metastatic capacity and implicated the
CCR4-NOT complex as a novel determinant of tumor cell metastatic potential [10].
The CCR4-NOT complex is a modular, multifunctional protein complex highly conserved
in eukarya [11]. Components of CCR4-NOT are found both in the nucleus and cytoplasm, and
mediate transcriptional and post-transcriptional regulatory functions [12, 13]. In mammalian
cells, CCR4-NOT has reported roles in epigenetically mediated transcriptional regulation [14],
nuclear hormone receptor-mediated transcription [15], and initiation of transcript decay by
deadenylation [16–18]. These observations suggest that the CCR4-NOT complex is a pleiotro-
pic regulator of transcript abundance.
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Cnot2 depletion has been shown to disrupt CCR4-NOT deadenylase activity [19] which
may be expected to alter metastasis-associated transcriptional programs. The absence of
CNOT2 catalytic activity led us to hypothesize that other CCR4-NOT effector functions may
drive metastasis. Moreover, the co-expression network analyses that identified Cnot2 also
implicated the CCR4-NOT deadenylase Cnot8 and its binding partner Tob1 as candidate
metastasis driving genes [10], suggesting that CCR4-NOT deadenylase function may be an
important determinant for metastatic progression.
Deadenylation, the progressive 3’-to-5’ shortening of the polyA tail, is a rate-limiting step of
transcript destabilization [20]. Translational inhibition and transcript decay mediated by
microRNAs [21], AU-rich elements [22], RNA binding proteins [23–25], and nonsense-medi-
ated decay [26] occur through the recruitment of deadenylase complexes. The CCR4-NOT
complex therefore plays an important role in maintaining mRNA equilibrium and coordinated
control of transcriptional programs. We previously demonstrated that modulation of tran-
scriptional elongation, mediated by Brd4 [27], significantly altered the metastatic capacity of
mammary tumor cells. In this study we extend these results by demonstrating that transcrip-
tional decay, mediated by the deadenylation activity of Cnot7 is also an important determinant
in tumor progression. Our findings are consistent with the existence of post-transcriptional
regulatory deadenylase complexes that promote metastasis by destabilizing metastasis suppres-
sive transcriptional programs. Importantly, our work identifies CNOT7 deadenylase activity as
a novel therapeutic target for anti-metastatic therapy.
Results
Cnot7 depletion suppresses tumor cell autonomous metastatic capacity
Metastasis assays by orthotopic implantation were performed to test if perturbation of Cnot7
or Cnot8 expression alters metastatic capacity. Cnot7 was knocked down in three independent
murine mammary tumor cell lines [28, 29] by stable transduction of short hairpin RNAs
(shRNAs), resulting in reductions of protein and transcript abundance (Fig 1). Cnot8 was
knocked down with the same method in 6DT1 and Mvt1 cells. After selection, transduced cells
were implanted into the fourth mammary fat pad of syngeneic mice. At assay endpoint (t = 30
days), Cnot8 knockdown did not produce consistent results between the tested cell lines (S1
Fig) and therefore was not included in further studies. Cnot7 knockdown consistently reduced
pulmonary metastasis without significant effect on primary tumor mass in vivo (Fig 1).
To validate these results in an independent experimental system we next assessed the effect
of diminished Cnot7 expression in an autochthonous transgene-driven metastasis model. The
MMTV-PyMT transgenic mammary tumor model [30] was bred to Cnot7 hemizygous knock-
out [31] mice to produce PyMT+ Cnot7+/- and PyMT+ Cnot7 wild type mice (Fig 2A). Quanti-
tative real time polymerase chain reaction analysis confirmed that Cnot7+/- mice expressed
Cnot7 transcript approximately two-fold lower than wildtype mice in the spleen and tumor
(Fig 2B & 2C). Consistent with observations in the orthotopic metastasis model, deletion of
one copy of Cnot7 significantly reduced the metastatic incidence and burden with no effect on
primary tumor mass (Fig 2D–2F).
To test if reduction of Cnot7 expression in the stroma influenced metastasis, we then crossed
C57BL/6J Cnot7+/- to FVB/NJ or Balb/cJ mice to generate Cnot7+/- and Cnot7+/+ mice that are
immune-tolerant to the FVB- or BALB-derived tumor cells, respectively (Fig 3A). Wild type
tumor cells were then orthotopically implanted into Cnot7+/- and Cnot7+/+ mice and animals
were aged for 28 days prior to necropsy. No consistent difference in tumor mass or metastasis
was observed (Fig 3B–3J) suggesting the primary role of Cnot7 in metastatic progression is
tumor cell-autonomous.
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Fig 1. Results of Cnot7 knockdown experiments for the cell lines 6DT1, Mvt1, and 4T1.Characterization of shRNA knockdowns at the protein (A-C) and
mRNA (D-F) levels are shown across the top of the figure. The upper band in the western blots is a non-specific band that appears with some batches of α-
CNOT7 antibody. The mass of orthotopically implanted tumors at necropsy is displayed in panels G, H, and I. The number of macroscopic pulmonary surface
metastases at necropsy for each cell line is presented in panels J, K, and L. The number of macroscopic pulmonary surface metastases after normalization
for primary tumor burden is displayed in panels M, N, and O. N.S. = not significantly different. * = p< 0.05; ** = p<0.01; *** = p<0.001.
doi:10.1371/journal.pgen.1005820.g001
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Tumor cell colonization of distant organs is thought to be the rate-limiting step of the meta-
static cascade [32, 33]. Lung colonization assays were therefore performed by intravenous
injection of Cnot7-depleted tumor cells into the tail vein of mice (Fig 4A). Three of four Cnot7
knockdown conditions resulted in significant suppression of lung colonization (Fig 4B–4D).
Cross-sectional area of metastatic lesions was subsequently measured in hematoxylin and
eosin (H&E) stained lung sections to determine if differences in colonization occurred second-
ary to proliferative differences. No difference in metastatic size between control and Cnot7-
depleted cells was observed for either 6DT1 or 4T1 cells (Fig 4E & 4F). These results are consis-
tent with a role of Cnot7 promoting early stages of lung colonization in a proliferation-inde-
pendent manner.
In vitro analysis of the effect of Cnot7 depletion
To investigate the potential cellular mechanisms underlying the suppression of metastatic
capacity upon Cnot7 depletion proliferation, motility, and colony formation in low attachment
conditions were assessed. Cnot7 depletion resulted in a consistent reduction of cellular prolifer-
ation in all three cell lines tested (S2 Fig) although, as noted above, this proliferative suppres-
sion was not observed in the in vivo orthotopic implantation assays.
Fig 2. (A) Design of the MMTV-PyMT xCnot7 knockout mouse cross experiment. (B) Relative expression of Cnot7mRNA in the spleens of control and
heterozygous knockout animals. (C) Relative expression of Cnot7mRNA in bulk primary tumors of control and heterozygous knockout animals. (D)
Incidence of macroscopic pulmonary metastases (mets) for the PyMT+ Cnot7+/+ and PyMT+ Cnot7+/- animals. The number of animals in each group is
indicated by the numbers in the histogram bars. (E) Mean number and standard deviation of metastases observed for the PyMT+ Cnot7+/+ and PyMT+
Cnot7+/- animals. Median values for each genotype are indicated by white line across the histogram bar. (F) Total tumor mass for the PyMT+ Cnot7+/+ and
PyMT+ Cnot7+/- animals. N.S. = not significantly different. * = p< 0.05.
doi:10.1371/journal.pgen.1005820.g002
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Fig 3. Design of the orthotopic implantation assays to test for stromal effects ofCnot7 knockdown (A). Dot plots showing the primary tumor mass of
each animal are shown for the cell lines 6TD1 (B), Mvt1 (C) and 4T1 (D). Surface pulmonary metastasis counts for each cell line are displayed in panels E, F,
and G. Metastasis counts after normalization by primary tumor burden are displayed in panels H, I, and J. N.S. = not significantly different. * = p< 0.05.
doi:10.1371/journal.pgen.1005820.g003
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Motility assays were performed on Cnot7 depleted 6DT1 and Mvt1 cells. Cnot7 knockdown
in Mvt1 cells resulted in a reduced motility in a wound healing assay. In contrast, Cnot7 knock-
down in 6DT1 using the same shRNA constructs showed no consistent difference in motility
as measured by wound healing assay (S2 Fig). Similar discrepancies across cell lines were
observed in soft agar assays, where Cnot7 depletion in 6DT1 resulted in significant reduction
of colony formation while no difference was observed in Mvt1 cells (S2 Fig). Due to the lack of
consistency among the in vitro assays, wound healing and soft agar assays were not performed
for 4T1 Cnot7 depleted cell lines. Overall the ambiguous results of the in vitro assays suggested
that further investigations into the mechanisms of the role of Cnot7 in metastatic disease
would be best examined in vivo. Further efforts therefore focused on metastatic capacity based
on orthotopic transplant assays.
Cnot7-mediated metastasis promotion is dependent on its deadenylase
activity
The CCR4-NOT complex has been implicated in multiple cellular functions, including RNA
deadenylation and degradation as well as transcriptional control [12]. To determine whether
CNOT7-mediated metastasis promotion was deadenylase-dependent, we stably expressed the
wild type and a deadenylase-inactive point mutant (D40A) [34–36] in mammary tumor cell
Fig 4. (A) Schematic of the experimental metastasis assay. Surface pulmonary metastases counts for 6DT1 are displayed in (B) and in (C) for 4T1. D)
Representative H&E stained lung sections are shown for the 6DT1 experiment. Relative metastasis size is indicated in panel (E) for 6DT1 and (F) for 4T1. N.
S. = not significantly different. * = p< 0.05; *** = p< 0.001.
doi:10.1371/journal.pgen.1005820.g004
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lines. Transduced cultures were selected for approximately equal expression of CNOT7 and
D40A protein (Fig 5A–5C), and used for in vivo orthotopic transplant assays.
Ectopic expression of CNOT7 or the D40A mutant showed no differences in primary tumor
mass in Mvt1 or 6DT1 cells (Fig 5D & 5F). However, CNOT7 but not D40A significantly pro-
moted metastatic burden for 6DT1 and Mvt1 (Fig 5G, 5I, 5J and 5L). In 4T1 cells, a statistically
significant increase in tumor mass was observed for CNOT7 but not for D40A expressing cells
(Fig 5E). Normalization of metastatic burden by tumor mass to account for difference in pri-
mary tumor growth still resulted in a significant difference in metastatic capacity for CNOT7
expressing 6DT1 or 4T1 cells and borderline significance in Mvt1 cells. Furthermore, although
the 4T1 D40A expressing cells exhibited increased metastasis compared to control, a significant
reduction of metastatic capacity was observed compared to CNOT7-wild type expressing cells
(Fig 5H and 5K). Overall these results are consistent with a major role of the deadenylase func-
tion of CNOT7 in modulating metastatic capacity of mammary tumor cell lines.
CNOT7 modulation of metastasis requires interaction with the
CCR4-NOT-associated adaptor proteins TOB1 and CNOT1
CNOT7 is a non-specific RNA-binding deadenylase protein [35]. Specificity for transcripts is
mediated by sequence specific RNA binding proteins that interact with the CCR4-NOT com-
plex. TOB1 is an adaptor protein that recruits CNOT7 to specific RNA-binding proteins, while
CNOT1 is a scaffolding protein for the CCR4-NOT complex [37, 38] (Fig 6A and 6B). Previous
work from our laboratory found that Tob1 expression was correlated with metastasis in the
[PyMT x AKXDn]F1 mice [10] (Fig 6C). In addition, human breast cancer datasets–available
through the Gene expression-based Outcome for Breast cancer Online (GOBO) database, an
expression array-based meta-analysis data set of 1,881 breast cancer patients [39]–also showed
that high expression of either TOB1 or CNOT1 correlated with poor survival (Fig 6D & 6E).
Furthermore TOB1 has previously been associated with poor distant metastasis free survival in
breast cancer patients [40].
Orthotopic metastasis assays were conducted to test the role of the CCR4-NOT adaptor
proteins in metastatic disease. Attempts to generate stable Cnot1 knockdown cells were unsuc-
cessful and therefore orthotopic assays were not performed. Tob1 knockdown in 6DT1 cells
(Fig 6F) showed diminished metastasis with no effect on primary tumor mass (Fig 6G–6J).
Experimental metastasis assays showed that Tob1 knockdown suppressed lung colonization of
6DT1 cells (Fig 6K), consistent with Tob1 acting at the same stage of the invasion-metastasis
cascade as Cnot7. In 4T1 cells, Tob1 knockdown suppressed tumor mass and pulmonary
metastasis (S3 Fig). Significant suppression of metastasis was observed after normalizing by
tumor mass, consistent with an effect other than just on tumor growth (S3 Fig).
To test if CNOT7-mediated metastasis promotion was dependent on a complex with TOB1
or CNOT1, we constructed expression vectors of CNOT7mutants that disrupted interaction
with TOB1 or CNOT1. CNOT7 E247A/Y260A mutations have previously been shown to dis-
rupt interaction with BTG/TOB family proteins but maintain interaction to CNOT1 [36]. Con-
versely, CNOT7 M141R substitution abolishes complex formation between CNOT7 and
CNOT1 [34], but interaction with TOB1 has not previously been assessed. Co-immunoprecipi-
tation (IP) experiments were therefore performed to address this question. As expected, IP of
CNOT7 E247A/Y260A but CNOT7 M141R co-precipitated CNOT1. In contrast, the CNOT7
M141R mutant retained the ability to co-precipitate TOB1 but no longer interacted with
CNOT1 (Fig 7A & 7B), indicating that the two mutant constructs specifically disrupted inter-
action with the TOB1 or CNOT1 adaptor proteins.
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Fig 5. Western blots showing the relative expression of exogenously expressed CNOT7 and the D40Amutant in 6DT1 (A), 4T1 (B) and Mvt1 (C).
The ectopically expressed CNOT7 migrates slightly higher than the endogenous band due to the addition of the FLAG epitope tag. The cell lines injected for
4T1 and Mvt1 experiments are indicated below the panels by arrows. Primary tumor burden for the CNOT7 or D40Amutant cell lines are indicated in panels
D-F. Surface pulmonary metastases (G-I) and metastases normalized for primary tumor mass (J-L) are displayed on the last two rows of the figure. N.S. = not
significantly different. * = p< 0.05; ** = p< 0.01; *** = p< 0.001.
doi:10.1371/journal.pgen.1005820.g005
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Fig 6. Schematic models of mRNA recruitment to CNOT7 by TOB1 (A) or CNOT1 (B). Correlation plot of Tob1 expression levels with metastatic capacity
in the AKXD recombinant inbred mouse panel (C). Kaplan-Meier analysis of the expression of TOB1 (D) or CNOT1 (E) and distant metastasis free survival
(DMFS) in the GOBOmeta-dataset. Western blot demonstrating the reduction of TOB1 mRNA levels by shRNA knockdown (F). Representative whole
mounts of lungs from the Tob1 knockdown spontaneous metastasis assay (G). Dot plots for surface pulmonary metastases from the Tob1 knockdown
spontaneous metastasis assay (H). Primary tumor burden for the orthotopically implanted tumors in the Tob1 knockdown assay (I). Surface pulmonary
metastases for the Tob1 knockdowns after normalization by primary tumor weight (J). Dot plots of pulmonary metastases for the experimental tail vein
injection assay (K). N.S. = not significantly different. * = p< 0.05; ** = p< 0.01; *** = p< 0.001.
doi:10.1371/journal.pgen.1005820.g006
Post-transcriptional Control of Metastasis by CNOT7
PLOSGenetics | DOI:10.1371/journal.pgen.1005820 January 25, 2016 10 / 23
Fig 7. Co-immunoprecipitation of theCnot7mutants confirming the specific disruption of interaction with TOB1 by the E247A/Y260Amutant (A).
Co-immunoprecipitation of theCnot7mutants confirming the specific disruption of interaction with CNOT1 by the M141Rmutant (B). Western blot confirming
the equal expression of Cnot7 constructs in cells used for spontaneous metastasis assays (C). Dot plot of the primary tumor mass for Cnot7wildtype and
mutant cells orthotopically implanted into mice (D). Surface metastasis plot results of orthotopically implanted 4T1 cells expressing mutantCnot7 constructs
(E). Dot plot of the surface pulmonary metastasis count for orthotopically constructs normalized for primary tumor burden (F).
doi:10.1371/journal.pgen.1005820.g007
Post-transcriptional Control of Metastasis by CNOT7
PLOSGenetics | DOI:10.1371/journal.pgen.1005820 January 25, 2016 11 / 23
CNOT7 and the mutant constructs were then expressed in 4T1 cells to achieve equal levels
of CNOT7, CNOT7 E247A/Y260A, and CNOT7 M141R protein (Fig 7C) and the cells were
then implanted orthotopically into mice. No significant changes in the rate of tumor growth or
primary tumor mass at endpoint were observed (Fig 7D). Consistent with previous observa-
tions, overexpression of CNOT7 promoted tumor cell metastatic potential but expression of
CNOT7 E247A/Y260A or CNOT7 M141R showed no change in metastasis compared to con-
trol (Fig 7E and 7F). These results indicate that CNOT7-mediated metastasis promotion
depends on contact with both TOB1 and CNOT1.
Cnot7 inversely-regulated transcripts are enriched for specific RNA
binding motifs
The above results suggest that Cnot7mediates its effect on metastasis by modulating the RNA
equilibrium. Therefore, to gain a better idea of the global gene expression program affected by
Cnot7, we identified mRNAs that exhibited an inverse relationship with Cnot7 expression in
4T1 cells in which Cnot7 was knocked down or over-expressed. Array-based transcriptome
analysis yielded 842 significantly dysregulated transcripts (p<0.01, S1 Table). Of these, 514
transcripts were upregulated upon Cnot7 knockdown and down-regulated upon CNOT7 over-
expression (t<0, S1 Table; Cnot7-anticorrelated transcripts). 3’ untranslated regions (3’UTRs)
were then interrogated for known consensus RNA-binding protein (RBP) sequence motifs
enriched in the Cnot7 inversely-correlated transcripts (S4 Fig). The inversely correlated tran-
scripts showed enrichment for the cytoplasmic polyadenylation element (CPE) [41], Pumilio
binding element (PUM) [42], Nanos response elements (NRE) [43], and cleavage and polyade-
nylation stimulation factor binding element (CPSF) [44]. In contrast neither permissive
(AUUUA) nor stringent (UUAUUUAUU) AU-rich elements (ARE) [45] were found to be
enriched indicating that, in 4T1 cells, Cnot7 preferentially mediates the degradation of a spe-
cific subset of mRNAs (S4 Fig).
RIP-Seq identifies a prognostic set of mRNAs directly regulated by
Cnot7
To identify transcripts directly regulated by CNOT7, RNA-immunoprecipitation was per-
formed using the anti-FLAG (M2) antibody in 4T1 cells overexpressing FLAG-CNOT7. Co-
precipitated RNA was subjected to high throughput sequencing (RIP-seq). 149 transcripts
showed enrichment relative to input and control (M2 RIP in 4T1 empty vector cells not
expressing FLAG-CNOT7) and showed an inverse correlation with Cnot7 expression (Fig 8A).
These transcripts showed 3’UTR enrichment for CPE, CPSF, and NRE sites (Fig 8B). PUM and
ARE sites were not considered since fewer than 10 of the 149 genes contained these binding
motifs. Seventy-one of 149 transcripts (48%) possessed CPE, CPSF, and NRE sites (Fig 8C, S2
Table) suggesting that CPEB, CPSF, and Nanos family proteins may collectively constitute
specificity factors that cooperatively drive metastasis by targeting CNOT7 to metastasis-associ-
ated transcripts.
We next tested if the 71 transcripts that shared the tripartite motif were prognostic in
human breast cancer data sets. Forty-six (65%) human orthologs of the CPE/CPSF/NRE con-
taining genes were present in GOBO [39] (S3 Table). These 46 genes were applied as a gene sig-
nature, weighted by their inverse correlation with CNOT7 expression, to determine whether
they could discriminate patient outcome. Consistent with the possibility that CNOT7 drives
progression by degrading metastasis suppressing mRNAs, high expression of the signature was
correlated with favorable distant metastasis free survival (DMFS, Fig 8D).
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Fig 8. Overlap between transcripts identified by RNA immunoprecipitation (RNA-IP) and the microarray analyses (A). RNA binding protein motif
enrichment for the RIP-seq transcripts (B). Overlap analysis of the CPE, CPSF and NRE RNA binding protein motifs in the 149 transcripts in common
between the RIP-seq and microarray experiment (C). Kaplan-Meier analysis of the GOBOmeta-dataset using as a weighted gene signature the 46
represented human orthologs of the 71 tripartite motif-possessing transcripts detected by RIP-seq (D). Results of genome-wide analysis of transcripts
containing predicted CPE, CPSF and NRE RNA protein binding motifs (E). Overlap of this gene set with theCnot7 inversely correlated genes from the
microarray analysis identified 293 genes in common. Kaplan-Meier analysis of GOBOmeta-dataset using the 293 CPE/CPSF/NRE tripartite transcripts as a
weighted gene signature (F).
doi:10.1371/journal.pgen.1005820.g008
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Global screen for putative CPE/CPSF/NRE Cnot7 target genes
Since CNOT7-bound and inversely regulated transcripts were reproducibly enriched for the
CPE/CPSF/NRE motifs, we speculated that this tripartite motif may specify CNOT7 target tran-
scripts, which are enriched for metastasis-associated genes. We thus interrogated the entire
genome for transcripts that possessed CPE, CPSF, and NRE 3’UTR elements, and filtered this
set for those transcripts expressed in 4T1 cells. This analysis identified 3424 genes (12.5% of the
mouse genome, Fig 8E). Filtering this set for those inversely-correlated with Cnot7 expression
yielded 293 genes (S4 Table). Human orthologs for 217 (74%) of the 293 genes were available in
GOBO, and were able to significantly discriminate DMFS (Fig 8F). High expression of this sig-
nature predicted favorable survival, suggesting that this set of tripartite motif containing, Cnot7-
anticorrelated transcripts constituted a metastasis suppressive post-transcriptional program.
Subjecting this 293-gene set to Ingenuity Pathway Analysis identified cancer as the most
highly represented disease annotation, with 247 (84%) transcripts previously annotated as can-
cer-associated. The top five represented canonical pathways associated with extravasation sig-
naling, and cancer-associated HER2 signaling, HGF signaling, and MAPK-signaling. The top
five upstream regulators in this network included Kras, Erbb2, and Tgfb1 signaling (S5 Table).
Gene sets regulated by each of these upstream regulators predicted distant metastasis free sur-
vival (S5 Fig). Consistent with our model, Erbb2 and Kras are previously reported upstream
signaling components that regulate the activity of CNOT7 adaptor and deadenylation cofactor
TOB1, transducer of ERBB2 [46, 47].
Discussion
CCR4-NOT is a highly conserved protein complex that has been implicated in diverse func-
tions associated with gene regulation [12, 13]. It exists in both cytoplasmic and nuclear forms
and is thought to play different roles depending on its subcellular localization and subunit
composition [12]. In the nucleus the CCR4-NOT complex has been implicated in numerous
activities, including chromatin modification, transcriptional elongation, RNA export, nuclear
RNA surveillance and transcription-coupled DNA repair [14, 15]. In the cytoplasm the
CCR4-NOT complex is thought to be the main RNA deadenylase, initiating both mRNA decay
and translational repression by polyA tail shortening [12, 13]. The CCR4-NOT complex also
participates in miRNA-mediated gene silencing through interactions with the GW182/Argo-
naute complex [21]. This large, multi-functional protein complex therefore has the potential to
play a variety of important roles in establishing and maintaining cellular function and response
to extracellular cues.
Previously our laboratory implicated the CCR4-NOT complex as an important determinant
for metastatic mammary cancer. Generation of co-expressed gene maps from mouse strains
with differing inherited sensitivity for pulmonary metastasis identified a network module cen-
tered on the CCR4-NOT component Cnot2 that was capable of discriminating breast cancer
patient outcome. Furthermore, in vivomodeling demonstrated that suppression or over-
expression of CNOT2 within tumor cells resulted in enhanced or reduced pulmonary metasta-
ses, respectively, indicating that Cnot2 has metastasis suppressing activities [10]. CNOT2 how-
ever does not have known enzymatic activities [48]. CNOT2 coordinates the interaction of
CNOT3 with the core CCR4-NOT complex, as well as additional regulatory molecules includ-
ing HDAC3 [14]. Despite lacking catalytic function, CNOT2 has been shown to be an impor-
tant positive regulator of CCR4-NOT deadenylase activity [19], cellular apoptosis, and mouse
embryonic stem cell pluripotency [49]. The contribution of Cnot2 to metastatic capacity
through the CCR4-NOT complex could therefore occur through a variety of CCR4-NOT
molecular functions.
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In this study we have begun to dissect the role of CCR4-NOT in mammary tumor metasta-
sis by investigating the role of RNA deadenylation in tumor progression. The integrated genet-
ics and gene expression analysis that initially identified Cnot2 also implicated other genes
associated with RNA deadenylation (Cnot8, Angel2, Tob1) as potential modulators of meta-
static disease, suggesting that this function of CCR4-NOT might be a critical determinant [10].
Bioinformatics analysis indicated that CNOT8 and TOB1 were associated with distant metasta-
sis free survival in human patients. We therefore selected Cnot8 and its highly conserved para-
log Cnot7 to determine whether the deadenylation function of CCR4-NOT plays a critical role
in tumor progression.
Cnot7 and Cnot8 are members of the DEDD superfamily of deadenylases [35]. Both genes
are expressed ubiquitously in tissues of adult animals [50] and are thought to have overlapping
functions [36]. Biochemical studies suggest that only one of the two proteins exist in the
CCR4-NOT complex at a time, suggesting unique functions for the mutually exclusive
CNOT7- or CNOT8-containing complexes, in addition to redundant functions [34, 51]. This
interpretation is consistent with the differing results observed for the shRNA knockdowns of
the two genes in our studies. Cnot7 knockdown had little or no effect on primary tumor
growth, indicating that its role in tumor progression is related to the metastatic process. In con-
trast Cnot8 suppressed both primary tumor growth and metastatic disease, suggesting a more
general role in regulating tumor cell proliferation. Further elucidation of the commonalities
and differences in molecular pathways controlled by these two deadenylases would likely pro-
vide interesting insights into tumor growth and progression.
Importantly, due to the multifunctional nature of the CCR4-NOT complex, the ability of
Cnot7 to promote metastatic disease was dependent on deadenylase activity. Point mutations
eliminating enzymatic activity or that disrupted interactions mediating recruitment of RNA
binding proteins to the CCR4-NOT complex suppressed the pro-metastatic activity of
CNOT7. Knockdown of the adaptor protein TOB1, which acts as a bridge between CNOT7
and RNA binding proteins CPEB3 and CPEB4, which recruit RNAs to the complex for deade-
nylation, had similar effects. Attempts to knockdown CNOT1, which is responsible for recruit-
ment of the NANOS1 and PUM2 RNA binding proteins, was unsuccessful. However, due to
the central role of CNOT1 in the CCR4-NOT complex and increased apoptosis in CNOT1-de-
pleted cells [52–54], this result was not unexpected. Taken together however, the point mutant
and Tob1 depletion results suggest that the majority of the effect on metastasis was likely due
to the influence of CCR4-NOT on RNA equilibrium or translational efficiency, rather than on
the other many functions ascribed to the complex.
The CCR4-NOT complex is thought to be one of two general deadenylase complexes in
mammalian cells [18]. However, the difference in phenotypes for Cnot7 and Cnot8 knock-
downs suggest that the different complexes likely target overlapping subsets of RNAs within
the cell [36]. Alternatively, the two paralogs may be differentially expressed and regulate differ-
ent post-transcriptional programs in different cell types. To gain a better understanding of
what subset Cnot7-containing CCR4-NOT complexes target global gene expression analysis
was performed in two independent experiments. We focused specifically on genes that were
inversely correlated with Cnot7 levels to enrich for those that were likely direct targets rather
than those dysregulated due to secondary effects on the transcriptome. Since transcript recruit-
ment to the CCR4-NOT complex is specified by RNA binding proteins a screen for RNA bind-
ing proteins was performed [23–25, 38, 55][56]. This screen revealed an enrichment of some
but not all of the known RNA binding protein motifs, suggesting that the Cnot7metastatic sup-
pressive program is mediated by specific RNA binding partners. Further investigation of these
RNA binding proteins and their RNA targets will likely provide additional insights into the
molecular pathways important for metastatic progression.
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Encouragingly enrichment of three of the four RNA binding protein motifs (CPE, CPSF
and NRE) was replicated in the Cnot7 RIP-seq experiment, providing more direct evidence of
the interaction of the CNOT7-containing CCR4-NOT complex with the Cpsf, Nanos and Cpeb
families of RNA binding proteins. Furthermore, almost half (71/149) of the RNAs identified by
the RNA-immunoprecipitation contained all three motifs. When used as a weighted gene sig-
nature, this set of transcripts was capable of discriminating metastasis outcome in human
breast cancer. Global transcriptome analysis in 4T1 mammary tumor cells revealed only 293
expressed genes bearing all three RNA binding protein motifs, consistent with previous find-
ings of only limited numbers of genes changing after Cnot7 knockdown [36]. Like the 71 genes
identified by RIP-Seq, the 293 triple motif containing genes effectively discriminate outcome in
breast cancer patients, suggesting enrichment of genes and molecular functions associated with
breast cancer patients. This interpretation was further supported by pathway analysis, which
identified previously known metastasis-associated functions such as extravasation and Tgfb1
signaling as enriched in the 293-gene set.
Overall this study supports the hypothesis that in addition to initiation of specific transcrip-
tional programs, such as epithelial-to-mesenchymal transition, degradation of specific RNAs
may play an important role in the establishment of metastatic capacity. Further investigations
of the RNA binding proteins that recruit transcripts for deadenylation and studies into possible
roles of the other CCR4-NOT deadenylase subunits Cnot6 and Cnot6l in metastatic progres-
sion may reveal additional important insights into tumor autonomous metastatic mechanisms.
Moreover, these results also suggest that targeting Cnot7 deadenylase activity may be useful for
anti-metastatic therapy. Cnot7 knockout animals are viable, with limited known phenotypes,
indicating that pharmaceutical suppression of Cnot7 deadenylase activity may not be unaccept-
ably toxic in the clinic. If true, this would provide a novel class of therapeutic agents to suppress
colonization or the emergence of disseminated but dormant tumor cells, ultimately leading to a
reduction in the morbidity and mortality associated with metastatic disease.
Materials and Methods
Ethics statement
The research described in this study was performed under the Animal Study Protocol LCBG-
004, approved by the NCI Bethesda Animal Use and Care Committee. Animal euthanasia was
performed by cervical dislocation after anesthesia by Avertin.
Cell lines and culture conditions
The mouse mammary carcinoma cell lines 4T1, 6DT1, Mvt-1 [28] (provided by Dr. Lalage
Wakefield) and human embryonic kidney HEK293 cells were cultured in Dulbecco’s Modified
Eagle Medium (DMEM) (Gibco) supplemented with L-Glutamate (Gibco), 9% fetal bovine
serum (FBS) (Gemini BioProducts), and 1% Penicillin and Streptomycin (P/S) (Gemini
BioProducts).
Lentiviral transduction
Two milliliter suspensions of 105 cells were incubated at 37°C in 5% CO2 overnight. Cells were
then infected with lentivirus suspension, and selected 30 hours post-infection with 5mg/mL
blasticidin for over-expression (Invitrogen) constructs or 10ug/mL (shRNA) puromycin for
shRNA constructs.
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Co-immunoprecipitation
Co-immunoprecipitation was conducted as described in [57] using mouse origin anti-FLAG
and Protein G Dynabeads magnetic beads (Invitrogen).
In vitro cell line assays
Proliferation and wound healing assays were performed on the Incucyte ZOOM (Essen BioSci-
ence) system following the previously described protocols [58]. For soft agar assays, 5,000 tryp-
sinized cells were seeded in triplicate in 0.4% low-melting-point agarose (Sigma) on top of a
1% agarose layer and colonies enumerated 21 days later.
Expression array
Array-based transcriptome profiling of Cnot7-knockdown and CNOT7-overexpressing 4T1
tumor cells was performed on Affymetrix GeneChip Mouse Gene 1.0 ST arrays by the Microar-
ray Core in the NCI Laboratory of Molecular Technology.
Library preparation and RNA sequencing
Library preparation was performed using the NEBNext Ultra Directional RNA Library Prep
Kit for Illumina with NEBNext multiplexing oligos using manufacturer’s protocol. RNA
sequencing was conducted on the Illumina HiSeq 2500.
RNA isolation, reverse transcription and Real-Time Polymerase Chain
Reaction
RNA was isolated from tumors and cell lines using RNeasy kit (Qiagen) or TriPure (Roche)
and reverse transcribed using iScript (Bio-Rad). Real-Time PCR was conducted using Veri-
Quest SYBR Green qPCRMaster Mix (Affymetrix).
Lentivector cloning
cDNA sequences of human FLAG-CNOT7, FLAG-CNOT7-D40A, and FLAG-CNO-
T7-E247A/Y260A were describe previously [36]. Lentiviral expression vectors were produced
with Multisite Gateway recombination. An entry clone using the murine Pol2 promoter was
recombined with the cDNA entry clone and N-terminal entry clone encoding the MYC (EQK-
LISEEDL) or FLAG (DYKDDDDK) epitope tag into a Gateway destination vector pDest-658.
pDest-658 is a modified version of the pFUGW lentiviral vector which contains the enhanced
polypurine tract (PPT) and woodchuck regulatory element (WRE) to provide higher titer
virus. It also contains an antibiotic resistance gene for blasticidin resistance. Entry clones were
subcloned by Gateway Multisite LR recombination using the manufacturer’s protocols (Invi-
trogen). Expression clones were transformed into E. coli STBL3 cells to minimize unwanted
LTR repeat recombination, and verified by agarose gel electrophoresis and restriction digest.
Transfection-ready DNA for the final clones was prepared using the GenElute XP Maxiprep
kit (Sigma). A control vector (8166-M24-658) was generated by standard Gateway LR recombi-
nation of a stuffer fragment made up of a non-coding DNA into the pLenti6-V5-DEST vector
(Invitrogen). CNOT7 and CNOT7-D40A lentivector constructs were generated by the Protein
Expression Laboratory and the Viral Technology Group in NCI, Frederick, MD.
Site directed mutagenesis was employed to generate CNOT7-M141R mutant using the
primers listed in S6 Table. The cDNA segment containing these mutations was subcloned into
the wild type CNOT7 lentivector by restriction digest and ligation.
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Native RNA immunoprecipitation
4T1 cells expressing 8166-M24-658 control vector or FLAG-CNOT7 constructs were grown to
~85% confluence in ten 15cm culture plates. Cells were then rinsed with 15mL ice cold sterile
PBS, scraped off, pelleted (~1mL pellet), and snap frozen in liquid nitrogen. Cells were thawed
on ice and lysed in 3.5mL lysis buffer (100mM NaCl, 5mMMgCl2, 10mMHEPES (pH 7.3),
0.5% NP40, 200 units RNasin (Promega), Protease inhibitor cocktail (Roche)). The resulting
4mL of cell lysate was spun down twice at 21,000g for 20 minutes at 4°C. 40uL of lysate was
saved 1% input to confirm immunoprecipitation. 200uL of lysate was saved for 5% RNA-seq
input and was purified by TriPure (Roche) RNA extraction. 25uL beads per 1mL lysate of Pro-
tein G Dynabeads were blocked with 1mL 0.5% BSA in PBS at room temperature for 20 min-
utes then washed twice with 1mL NT2 wash buffer (50mM Tris-HCl (pH 7.4), 150mMNaCl,
1mMMgCl2, 0.05% NP40). 24ug antibody was added to each sample and incubated at 4°C
overnight then beads were added to each sample and rotated for 30 minutes at room tempera-
ture. Beads were washed four times in 1mL NT2 buffer. Eighty five percent of beads were sub-
jected to RNA extraction with TriPure. Protein from the remaining 15% of beads was eluted
with Laemli buffer to confirm immunoprecipitation.
Immunoblot and antibodies
Protein was extracted with Pierce lysis buffer, vigorously homogenized, and incubated on ice
for twenty minutes. 20ug lysate per sample in NuPage LDS Sample Buffer and NuPage Reduc-
ing Agent (Invitrogen) was used for western blotting. PVDF membrane (Millipore) containing
transferred proteins was incubated overnight in solution of 5% milk protein, tris-buffered
saline supplemented with 0.05% Tween-20, and primary antibody. The membrane was then
incubated with horse-radish peroxidase linked anti-mouse (GE Healthcare), anti-rat, or anti-
rabbit (Santa Cruz Biotechnology) IgG secondary antibodies. Immunoblot was visualized using
Amersham ECL Prime Western Blotting Detection System and Amersham Hyperfilm ECL
(GE Healthcare). Rabbit origin anti-CNOT7 was a generous provided by G. Sebastiaan Wink-
ler. Commercial antibodies used in this study include rabbit origin anti-TOB1 (GeneTex), rab-
bit origin anti-CNOT1 (Protein Tech), rat origin anti-HA (Roche), mouse origin monoclonal
anti-FLAG (M2, Sigma).
Animal studies
Female FVB/NJ or Balb/cJ mice from Jackson Laboratories were injected at 6–8 weeks of age.
Two days prior to orthotopic injections, cells were placed in non-selective media. On the day of
injection, 1x105 cells were injected orthotopically into the fourth mammary fat pad of age-
matched virgin females. After 30 days the mice were euthanized by intraperitoneal injection of
1mL Tribromoethanol with subsequent cervical dislocation. Primary tumors were resected,
weighed, and snap frozen in liquid nitrogen. Lungs were resected, surface metastases were
counted; lungs were inflated with 10% nitrate-buffered formalin and sent for sectioning and
staining. For tail vein injection, 105 were injected into the lateral tail vein, mice were euthanized
22 days post-injection. All procedures were performed under the Animal Safety Proposal
(LCBG-004) and approved by the NCI-Bethesda Animal Care and Use Committee.
Statistical analysis
Statistical analysis comparing two samples were conducted using the Mann-Whitney test on
Prism Version 5.03 (GraphPad Software, La Jolla, CA). Multiple-comparison data was
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analyzed by Kruskal-Wallis test with post-hoc Conover-Inman correction for multiple analyses
by R-script. Survival data was conducted with the Mantel-Cox test on Prism.
RBP motif sites were mapped on the 3’UTR regions of genome genes (27305 mRNA
FASTA format) by using a Perl script. RBP motif site enrichment analysis was performed by
the random sampling the genes from genome in the same number (the final overlapping gene
number) and calculate the numbers of the gene with the RBP motif site and of the RBP motif
site and repeat the sampling 1000 times. The p-value was estimated by one tail t-test. Differen-
tial gene expression analyses were done by t-test using the software package R.
Data access
Array-based gene expression and RIP-seq studies from this study have been submitted to the
NCBI Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/ under the acces-
sion numbers GSE73296 (array) and GSE73366 (RIP-seq).
Supporting Information
S1 Fig. Results of Cnot8 knockdown in vivo studies. Relative Cnot8mRNA depletion by
shRNA (arbitrary units)for 6DT1 and Mvt1 cells is shown in panels (A) and (B). Effects of
shRNA knockdown are shown for the primary tumor for 6DT1 (C) and Mvt1 (D) are shown at
the top of the figure. The macroscopic pulmonary surface metastases counts are shown in pan-
els (E) and (F). Macroscopic pulmonary surface metastases after normalization for primary
tumor mass are shown in panels (G) and (H). N.S. = not significantly different.  = p< 0.05; 
= p<0.01;  = p<0.001.
(EPS)
S2 Fig. Effect of Cnot7 depletion on the proliferation of 6DT1, Mvt1 and 4T1 cells (A).
Results of Cnot7 knock down on migration of 6DT1 and Mvt1 cells, as measured by wound
healing assays (B). Soft agar colony formation assays for 6DT1 and Mvt1 Cnot7 knock down
cell lines (C).
(EPS)
S3 Fig. Relative knockdown of Tob1mRNA in 4T1 cells (A). Primary tumor burden after
orthotopic transplantation of 4T1 Tob1-knockdown cells into BALB/c animals (B). Pulmonary
surface metastasis count of 4T1 Tob1-knockdown tumors (C). Tumor normalized metastasis
counts of 4T1 Tob1-knockdown cells (D).
(EPS)
S4 Fig. Permutation strategy to identify over-represented RNA binding protein motifs in
Cnot7 inversely-correlated transcripts from microarray analysis (A). Results of motif search
(B). The vertical red line represents the observed number of times a particular motif was found
in the Cnot7 inversely correlated gene set. The blue curve represents the predicted range based
on 1000 permutations.
(EPS)
S5 Fig. Kaplan-Meier analysis of the GOBOmeta-dataset using pathway enriched subsets
of the 293 CPE/CPSF/NRE tripartite 4T1 expressed transcripts. Gray lines indicate patients
with tumors that expressed the individual gene signatures below the median value. Red lines
indicate patients with tumors expressing the gene signatures above the median.
(EPS)
S1 Table. Genes dysregulated by overexpression or knockdown of Cnot7.
(XLS)
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S2 Table. Genes with negative expression correlations with Cnot7 whose mRNAs are asso-
ciated with the CNOT7 protein.
(XLS)
S3 Table. Human-mouse gene symbol matching for GOBO weighted gene signature prog-
nosis analysis.
(XLSX)
S4 Table. Genes with negatively correlated with Cnot7 expression that contain the CPE/
CPSF/NRE tripartite RNA binding protein motif.
(XLSX)
S5 Table. Ingenuity Pathway Analysis of CPE/CPSF/NRE bearing, Cnot7 negatively corre-
lated genes.
(XLS)
S6 Table. Primers and primer sequences used in this analysis.
(XLS)
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